Clinical Trials
3 trialsNCT06095505 2026-06-05
ALISCA-Lung1
Puma Biotechnology, Inc.
Phase 2 Recruiting
NCT04479306 2026-04-16
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT07465757 2026-03-12
ALISCA-Lung2
Puma Biotechnology, Inc.
Phase 2 Not yet recruiting